GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.

Autor: Liu I; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, 10117 Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, 10117 Berlin, Germany., Alencastro Veiga Cruzeiro G; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Bjerke L; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Rogers RF; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Grabovska Y; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Beck A; Center for Neuropathology, Ludwig-Maximilians-University, 81377 Munich, Germany., Mackay A; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Barron T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA., Hack OA; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Quezada MA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA., Molinari V; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Shaw ML; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Perez-Somarriba M; Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, Surrey SM2 5 NG, UK., Temelso S; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK., Raynaud F; Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RK, UK., Ruddle R; Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RK, UK., Panditharatna E; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Englinger B; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria., Mire HM; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Jiang L; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Nascimento A; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., LaBelle J; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Haase R; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Rozowsky J; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Neyazi S; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Baumgartner AC; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Castellani S; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Hoffman SE; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Cameron A; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Morrow M; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Nguyen QD; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Pericoli G; Department of Onco-haematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy., Madlener S; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria., Mayr L; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria., Dorfer C; Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria., Geyeregger R; Clinical Cell Biology, Children's Cancer Research Institute (CCRI), Vienna 1090, Austria., Rota C; Department of Neurobiology, Harvard Medical School, Boston, MA 02215, USA., Ricken G; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna 1090, Austria., Ligon KL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA., Alexandrescu S; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA., Cartaxo RT; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA., Lau B; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA., Uphadhyaya S; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA., Koschmann C; Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA., Braun E; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden., Danan-Gotthold M; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden., Hu L; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden., Siletti K; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden., Sundström E; Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 17177 Stockholm, Sweden., Hodge R; Allen Institute for Brain Science, Seattle, WA 98109, USA., Lein E; Allen Institute for Brain Science, Seattle, WA 98109, USA., Agnihotri S; Departments of Neurosurgery and Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA., Eisenstat DD; Murdoch Children's Research Institute, Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia., Stapleton S; Department of Neurosurgery, St George's Hospital NHS Trust, London SW17 0QT, UK., King A; Department of Neuropathology, King's College Hospital NHS Trust, London SE5 9RS, UK., Bleil C; Department of Neurosurgery, King's College Hospital NHS Trust, London SE5 9RS, UK., Mastronuzzi A; Department of Onco-haematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy., Cole KA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Waanders AJ; Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA., Montero Carcaboso A; Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain., Schüller U; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany., Hargrave D; University College London Great Ormond Street Institute for Child Health, London WC1N 1EH, UK., Vinci M; Department of Onco-haematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy., Carceller F; Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, Surrey SM2 5 NG, UK; Division of Clinical Studies, The Institute of Cancer Research, London SW7 3RK, UK., Haberler C; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna 1090, Austria., Slavc I; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria., Linnarsson S; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden., Gojo J; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria., Monje M; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford, CA, USA., Jones C; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey SM2 5 NG, UK. Electronic address: chris.jones@icr.ac.uk., Filbin MG; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: mariella.filbin@childrens.harvard.edu.

Publikováno v: Cancer cell [Cancer Cell] 2024 Aug 27. Date of Electronic Publication: 2024 Aug 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor.

Autor: Sánchez-Sierra N; Department of Pediatric Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Perez-Somarriba M; Neuro-Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain., Santa-Maria V; Neuro-Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain., Cruz O; Neuro-Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain., García-Rey E; Transfusion Service, Banc de Sang i Teixits, Hospital Sant Joan de Déu, Barcelona, Spain., Martorell L; Department of Molecular Genetics, Hospital Sant Joan de Déu, Barcelona, Spain., Rovira M; Haematology Department, Hospital Clínic, Barcelona, Spain.; Stem Cell Transplant Unit and Department of Hematology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Margarit A; Stem Cell Transplant Unit and Department of Hematology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Marsal J; Stem Cell Transplant Unit and Department of Hematology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain.

Publikováno v: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 May; Vol. 70 (5), pp. e30177. Date of Electronic Publication: 2023 Jan 10.

Clinical and Molecular Evolution of an ALK -Driven Infant-Type Hemispheric Glioma Treated Sequentially With Second- and Third-Generation Anaplastic Lymphoma Kinase Inhibitors.

Autor: Gene-Olaciregui N; Laboratory of Molecular Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Perez-Somarriba M; Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain.; Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Santa-María V; Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Cruz O; Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Gómez-González S; Laboratory of Developmental Tumor Biology, Institut de Recerca Sant Joan de Déu, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Castañeda A; Pediatric Solid Tumor Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Suñol M; Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain., Rovira C; Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain., Muchart J; Department of Radiology, Hospital Sant Joan de Déu, Barcelona, Spain., Hinojosa J; Department of Neurosurgery, Hospital Sant Joan de Déu, Barcelona, Spain., La Madrid AM; Neuro Oncology Unit, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain., Lavarino C; Laboratory of Molecular Oncology, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2023 Mar; Vol. 7, pp. e2200547.

Old drugs still work! Oral etoposide in a relapsed medulloblastoma

Autor: Perez-Somarriba M, Andión M, López-Pino MA, Lavarino C, Madero L, Lassaletta A

Publikováno v: CHILDS NERVOUS SYSTEM
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

Medulloblastoma is the most common malignant brain tumor in children. Approximately 30% of children with medulloblastoma will progress or relapse despite being treated. New therapies have been proposed in recent years, including high-dose chemotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0a01c001a33d438f43688765eec579a9
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15769